Loading patent…
OwnerNiklas Beyersdorf, Daniela Langenhorst +2inventors
InventorsNiklas Beyersdorf, Daniela Langenhorst, Peter F. Zipfel, Prasad Dasari
Estimating the term…
Invasive fungal disease (IFD) constitutes an increasing health concern due to growing numbers of patients at risk for opportunistic fungal infections. Among the fungi capable of inducing opportunistic infections the yeast Candida albicans is clinically the most important. Immune evasion proteins like the pH-regulated antigen 1 (Pra1) and the translation elongation factor 1 (Tef1), which are expressed on the fungal surface and are also secreted, are major drivers of pathogenicity. Therefore, novel monoclonal antibodies (mAb) binding these proteins have been developed. In an in vivo mouse model of high-dose septic C. albicans infection, therapeutic application of mAb against Pra1 reduced clinical symptoms of the disease. Prophylactically, mAb against Tef1 protected mice from clinical disease and prolonged survival. The mABs of the present invention may also be efficacious in patients at risk or with already established IFD.
Antibody directed against pH regulated antigen 1 (Pra1) of Candida albicans, or an antibody fragment thereof, comprising a complementarity-determining region 1 (CDR1), which comprises an amino acid sequence as defined by SEQ ID NO:1, a complementarity-determining region 2 (CDR2), which comprises an amino acid sequence as defined by SEQ ID NO:2. a complementarity-determining region 3 (CDR3), which comprises an amino acid sequence as defined by SEQ ID NO:3, a complementarity-determining region 4 (CDR4) as defined by SEQ ID NO:4, a complementarity-determining region 5 (CDR5), which comprises an amino acid sequence as defined by SEQ ID NO:5, and a complementarity-determining region 6 (CDR6), which comprises an amino acid sequence as defined by SEQ ID NO:6, wherein any one of the CDR sequences can be altered by substitution, deletion, or insertion of 1 or 2 amino acids.
Hybridoma cell line with Accession number DSM ACC 3369.
Antibody directed against translation elongation factor 1 (Tef1) of Candida albicans, or an antibody fragment thereof, comprising a complementarity-determining region 1 (CDR1), which comprises an amino acid sequence as defined by SEQ ID NO:7, a complementarity-determining region 2 (CDR2), which comprises an amino acid sequence as defined by SEQ ID NO:8, a complementarity-determining region 3 (CDR3), which comprises an amino acid sequence as defined by SEQ ID NO:9, a complementarity-determining region 4 (CDR4), which comprises an amino acid sequence as defined by SEQ ID NO:10, a complementarity-determining region 5 (CDR5), which comprises an amino acid sequence as defined by SEQ ID NO:
Hybridoma cell line with Accession number DSM ACC 3368.
Dependencies are inferred from the claim text.